IRulya Therapeutics Inc. (IRLA): Form 8-K filed 2026-11-13

Accepted by EDGAR: 2026-11-13 16:30 ET
Event date: 2026-11-13
Accession no.: 0001193125-26-460775
Original filing: SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

IRulya reports third quarter results and provides LAM-001 development update

IRulya reported a net loss of $27.7 million for the three months ended September 30, 2026, compared to $13.4 million a year earlier. Cash, cash equivalents and investments totaled $105.2 million, which the company expects to fund operations through the end of 2028. Its fully enrolled LAM-001 Phase 2 trial in bronchiolitis obliterans syndrome post lung transplant has data anticipated in the first quarter of 2027.

Net loss was $27.7 million, or $2.31 per basic and diluted share, for the three months ended September 30, 2026.
Cash, cash equivalents and investments were $105.2 million as of September 30, 2026.
The company expects its cash position to fund operations through the end of 2028.
The LAM-001 Phase 2 trial in BOS is fully enrolled, with data anticipated in the first quarter of 2027.

earningsguidanceproduct

Items reported

Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Documents

Type	Description	Document
8-K	8-K	d190919d8k.htm
EX-99.1	EX-99.1	d190919dex991.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.